What is going with the Noxopharm (ASX:NOX) share price today?

The Noxopharm Ltd (ASX: NOX) share price is bouncing around after the drug developer announced the progression of its NOXCOVID-1 trial.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Noxopharm Ltd (ASX: NOX) share price is raced higher on the open this morning. However, the Noxopharm share price has since settled down. The movement comes as a result of the clinical drug developer provided an update on its NOXCOVID trial.

At the time of writing, the share price is 2.9% higher, trading at 70 cents a share.

Drug trial advances moving the Noxopharm share price

Today's announcement from Noxopharm specified that its Veyonda drug has been approved to move to its final stage of the NOXCOVID-1 clinical trial.

The thumbs up for proceeding to the second and final stage comes after the company completed Part 1. This process involved 26 patients with moderate COVID-19 disease. As a part of the trial, Noxopharm assessed daily Veyonda doses of 400, 600, 800, 1200, and 1800 mg. It has been deemed that the 1,800 mg dosage was the most optimal. The high dosage exhibits evidence of the safety of using the developed drug.

CEO commentary

Noxopharm's CEO, Dr. Graham Kelly commented on the findings:

The high potency of Veyonda in blocking cytokine release from damaged tissue in the laboratory meant we were obliged to adopt a very cautious and methodical approach when being used for the first time in patients with poor lung function. We can now be confident that Veyonda, despite its potency, is well tolerated at a dosage we believe will be therapeutic.

The progression to Part 2 moves it closer to being an effective and safe treatment for septic shock. The company is excited about its potential, as septic shock is not only experienced by COVID-19 patients but is also one of the most common causes of human deaths in the event of infection and severe trauma.

What's next for Noxopharm?

From here, Part 2 of the trial will involve 10 to 15 patients with moderate to severe lung dysfunction.

The recruited patients will then be treated with the selected 1,800 mg dosage of Veyonda each day over 14 days.

Lastly, the company also noted:

Part 1 patient blood (Cohorts 1-4) currently is being analysed for 60 pro-inflammatory (cytokines, chemokines) factors in what the Company believes will be one of the most comprehensive analyses of its kind in COVID-19 disease.

The Noxopharm share price is now up 327% in the last 12 months. In comparison, the S&P/ASX 200 Index (ASX: XJO) is up 9.8% over the same period of time.

 

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »